![]() |
|
|
Vol. 57, Issue 6, 1104-1113, June 2000
Forschungsinstitut für Molekulare Pharmakologie (A.E., G.B., A.H., J.F., M.Be., M.Bi., W.R.) and Institut für Pharmakologie, Freie Universität Berlin (W.R.), Berlin, Germany
| |
Abstract |
|---|
|
|
|---|
A fusion protein consisting of the endothelin B (ETB) receptor and the enhanced green fluorescent protein (EGFP) in conjunction with Cyanin3- or fluorescein-conjugated endothelin 1 (Cy3-ET1, Fluo-ET1) was used to investigate the ligand-mediated internalization of the ETB receptor. The ETB receptor and the ETB/EGFP fusion protein displayed very similar pharmacological properties when expressed in Chinese hamster ovary cells. The integrity of the fusion protein was verified by low temperature PAGE analysis of the 125I-ET1-bound ETB receptor and the 125I-ET1-bound ETB/EGFP fusion protein. Fluorescence microscopy of Chinese hamster ovary cells expressing the ETB/EGFP fusion protein demonstrated strong signals at the plasma membrane. On addition of Cy3-ET1, internalization of ligand and receptor occurred within 5 min via a sucrose-sensitive (i.e., clathrin-mediated) pathway. On further incubation, ETB/EGFP and Cy3-ET1 fluorescences were found in the perinuclear region, colocalized with fluorescent low density lipoproteins, a marker of the late endosomal/lysosomal pathway, but not with fluorescent transferrin, a marker of the recycling pathway. No dissociation of Cy3-ET1 from the receptor was seen within 4 h. Using 125I-ET1 or Cy3-ET1, binding sites were again demonstrable at the cell surface within 2 h. The reappearance of binding sites was abolished by prior treatment of the cells with cycloheximide, an inhibitor of protein synthesis. The data demonstrate that the ligand-occupied ETB receptor is internalized; however, it does not recycle like most of the G protein-coupled receptors but is sorted to the late endosomal/lysosomal pathway in a manner similar to that of the family of protease-activated receptors.
| |
Introduction |
|---|
|
|
|---|
Endothelins
(ET1, ET2, ET3), which are among the most potent vasoactive molecules
(Yanagisawa et al., 1988
), act via two distinct endothelin receptors,
the ETA and ETB receptors
(Arai et al., 1990
, Sakurai et al., 1990
). Both receptors, members of
the large group of G protein-coupled receptors (GPCR), are expressed in smooth muscle cells, in which they mediate vasoconstriction (Seo et
al., 1994
). In contrast, only the ETB
receptor is expressed in endothelial cells; here it mediates
vasodilation by the generation of nitric oxide and prostacyclin (de
Nucci et al., 1988
). Both initial vasodilation and long-lasting
contraction were demonstrated in animals after administration of
endothelin as a bolus injection (Hoffman et al., 1989
; Le Monnier de
Gouville et al., 1990
), but only vasoconstriction was observed when ET1
was applied continuously (Goetz et al., 1989
, Hinojosa Laborde et al.,
1989
). Neither the mechanisms of the short vasodilatory and the long
vasoconstrictory responses to bolus application nor the exclusive
appearance of the vasoconstrictory response upon continuous application
are well understood. Different modes of desensitization,
internalization, intracellular trafficking, and resensitization of ET
receptors were proposed as explanations. Desensitization of the
ETA receptor was found to be retarded compared
with that of the ETB receptor (Cramer et al.,
1997
). However, according to another study, both receptors expressed in
human embryonic kidney 293 cells were desensitized by GPCR kinases
(GRK), in particular GRK2, with indistinguishable time courses
(Freedman et al., 1997
). Efficient desensitization was also found for
the ETB receptor coexpressed with a catalytically inactive GRK2 (K220/GRK2) and in the case of a mutant
ETB receptor lacking the C-terminal 40 amino
acids (Shibasaki et al., 1999
). Although the desensitization has been
studied for both endothelin receptors, the mode of internalization has
been analyzed only for the ETA receptor. In
stably transfected Chinese hamster ovary (CHO) cells, the receptor was
found to reside in caveolae and to be internalized after binding of ET1
(Chun et al., 1994
). Because a significant portion of the internalized
receptor/ligand complex remained undegraded within the cells for up to
2 h (Chun et al., 1995
), it was suggested that the presence of
this complex within the cell provided the basis for the prolonged
action of ETA receptors. Alternatively,
continuous recycling of ETA receptors upon
stimulation with ET1, as found in cultured rat aortic myocytes
(Marsault et al., 1993
), may underlie the prolonged signaling of
ETA receptors.
The mechanisms of internalization and intracellular transport of the
ETB receptor have not been analyzed up to now but
are of particular clinical importance, because the
ETB receptor is involved in the regulation of
vascular tone, renal sodium excretion, and possibly in the clearance of
plasma endothelin (for review, see Sokolovsky, 1995
). Moreover,
potential differences in the mode of internalization between
ETA and ETB receptors may
further contribute to the understanding of the transient
ETB receptor-mediated vasodilation and the
long-lasting ETA receptor-mediated
vasoconstriction. ET1-mediated receptor internalization and recycling,
however, are difficult to analyze by standard binding protocols
involving acidic stripping of the ligand, as ET1 forms a stable,
quasi-irreversible complex with the ETB receptor
(Waggoner et al., 1992
). Direct visualization of the receptor/ligand
complex, however, may help address the questions of how the
ligand-occupied receptor is internalized and whether ligand and
receptor follow the same or different intracellular routes. To this
end, we established CHO cells stably expressing either the
ETB receptor or a fusion protein comprising the
ETB receptor and the red-shifted variant of the
green fluorescent protein (EGFP). In addition, fluorochrome-conjugated
ET1 molecules were synthesized. By combining the use of
ETB/EGFP fusion proteins with fluorescent ET1, we
were able to visualize internalization and intracellular trafficking of
the ligand-occupied ETB receptor for up to 4 h. The route of intracellular trafficking was further characterized by
the use of fluorescent transferrin and low-density lipoproteins (LDL).
We demonstrate for the first time that ligand-occupied ETB receptor is internalized quantitatively and
that both receptor and ligand follow sorting via late endosomes. The
lack of recycling, so far only reported for the luteinizing
hormone/human choriogonadotropin receptor (LH/hCG; Ghinea et al., 1992
)
and the protease-activated receptors (PARs) (Hein et al., 1994
;
Déry et al., 1999
; Trejo and Coughlin, 1999
), results in a
transient down-regulation of the ETB receptor.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials. Ham's F12 medium, trypsin, cycloheximide, and lipofectin were from Life Technologies (Grand Island, NY), bacitracin and aprotinin from Merck (Darmstadt, Germany), G418 from Calbiochem-Novabiochem GmbH (Bad Soden, Germany), and fetal calf serum from PAN-SYSTEMS GmbH (Nürnberg, Germany). 125I-ET1 (2200 Ci/mmol) was from NEN (Boston, MA). BQ123 was from Alexis Corp. (Läufelfingen, Switzerland), ET3, BQ788 and PD145065 were from Calbiochem-Novabiochem GmbH. The plasmid pEGFP-N1, encoding the red-shifted variant of green fluorescent protein, was from Clontech Laboratories (Heidelberg, Germany). Tetramethylrhodamine isothiocyanate-conjugated transferrin (TRITC-Tfr), 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-conjugated LDL (DiI-LDL) and Hoe33258 were from Molecular Probes (Eugene, OR). All other reagents were from Sigma (München, Germany)
Peptide Synthesis and Fluorescence Labeling. ET1 was synthesized using the solid phase method (chlorotrityl-resin, 1.05 mmol/g; Calbiochem-Novabiochem GmbH) and standard 9-fluorenylmethoxy-carbonyl chemistry (double couplings with 8 Eq of 9-fluorenylmethoxy-carbonyl-amino acid derivatives). After the final cleavage/deblocking, the crude peptide (50 mg) was dissolved in 500 ml of aqueous 4 mM NaHCO3 solution and kept for 2 days at room temperature. The final purification was carried out by preparative HPLC (Polyencap A 300, 250 × 20 mm) applying a linear gradient 20 to 60% B within 70 min [A, trifluoroacetic acid/water (0.1:99.9, v/v); B, trifluoroacetic acid/acetonitrile/water (0.1:80:19.9, v/v/v)]. The mass of the purified peptide was verified by ES-MS {[M + H]: 2491.6 (found), 2491.0 (calculated)}.
Fluorescence labeling of ET1 was carried out by selective modification of the
-amino group of Lys-9 with Cyanin3 (Cy3) (Amersham Pharmacia
Biotech, Freiburg, Germany) or
5(6)-carboxyfluorescein-N-hydroxysuccinimide ester (Fluo;
Fluka Feinchemikalien GmbH, Neu-Ulm, Germany) in 0.1 M
NaHCO3 at pH 9.3 followed by preparative HPLC purification.
Cell Culture. CHO cells were maintained in Ham's F12 medium supplemented with 10% fetal calf serum, 100 U/ml penicillin G, and 100 µg/ml streptomycin sulfate at 37° C in a humidified atmosphere of 95% air, 5% CO2. For fluorescence microscopy or laser scanning microscopy, cells were grown on glass coverslips for 48 h. For biochemical analyses, cells were grown for 48 to 72 h to 80% confluence.
Generation of ETB Receptor/EGFP Expression Constructs. The plasmid pcDNA3.ETB harboring the cDNA encoding the human ETB receptor was kindly provided by Frank Zollmann (Institute for Clinical Pharmacology, Free University of Berlin, Germany). The cDNA encoding the human ETB receptor was amplified with a forward primer (5'-AGATACTGCAGCAGGTAGCAGCATGCAGCCG-3') introducing a PstI site (underlined) and the reverse primer (5'-CCAGTAATAAATACAGCTCATCGGATCCATT-3'), designed to both replace the original stop codon with an aspartate codon and to introduce a BamHI site (underlined). The PstI/BamHI cut PCR fragment was cloned into the PstI/BamHI cut plasmid pEGFPN1. The sequence of the resulting plasmid, pEGFP.ETB, was verified using the Big Dye Terminator kit (Applied Biosystems, Weiterstadt, Germany) with a set of four different sense and antisense primers (primer sequences are available upon request).
Generation of CHO Cell Clones Stably Expressing the
ETB Receptor.
The protocol for transfection and
isolation of clones, expressing either the ETB
receptor or the ETB/EGFP fusion protein, was
essentially similar to that described previously (Oksche et al., 1996
).
Membrane Preparation for Receptor Binding and Low
Temperature-Polyacrylamide Gel Electrophoresis (LT-PAGE).
CHO
cells expressing either the ETB receptor or the
ETB/EGFP fusion protein were grown on 100-mm
Petri dishes, washed twice with 5 ml of PBS (137 mM NaCl, 2.7 mM KCl,
1.5 mM KH2PO4, 8.0 mM
Na2HPO4, pH 7.4), harvested
with a rubber policeman and centrifuged at 400g for 10 min.
The pellet was resuspended in Tris-BAME buffer (50 mM Tris, 0.15 mM
bacitracin, 0.0015% aprotinin, 10 mM MgCl2, 2 mM
EGTA, pH 7.3), and the suspension was homogenized with a glass/Teflon
homogenizer (10 strokes), and centrifuged at 26,000g for 30 min. The pellet was rehomogenized in Tris-BAME and aliquots of the
resulting suspension were stored at
70°C until use.
LT-PAGE Analysis.
Membranes (50 µg) were incubated with
200 pM 125I-ET1 in 65 µl of Tris/BAME for
2 h at 25°C and stored on ice overnight. Aliquots (20 µl) were
mixed with 20 µl of sample buffer [0.12 M Tris/HCl, pH 6.8), 4%
(v/v) SDS, 10% (v/v)
-mercaptoethanol, 20% (w/v) glycerol, and
0.02% (w/v) bromphenol blue]. The samples were separated on 10%
SDS-polyacrylamide gels in the presence of 0.1% SDS at 4°C.
Prestained molecular weight standards (Bio-Rad, München, Germany)
were run in parallel. Gels were dried (onto Whatman 3 MM paper) at
65°C in a slab gel drier (SEM60; Hofer Scientific Instruments, San
Francisco, CA) overnight and exposed for 2 to 4 days on Kodak X-Omat or
BioMax film (Kodak, Rochester, NY).
125I-ET1 Displacement Binding Analysis.
Membranes (5 µg) were incubated in a final volume of 200 µl of
Tris/BAME buffer containing 20 pM 125I-ET1 alone
or increasing concentrations of unlabeled ligand (1 × 10
12 to 1 × 10
6
M) for 2 h at 25°C at 300 rpm in a shaking water bath. The
samples were then transferred onto GF/C filters (Whatman International Ltd., Maidstone, UK), pretreated with 0.1% (w/v) polyethylenimine and
washed rapidly twice with PBS using a Brandel cell harvester. Filters
were finally transferred into 5-ml vials and radioactivity was
determined in a liquid scintillation counter. Data were analyzed with
RadLig Software 4.0 (Cambridge, UK), and graphs were generated with
Prism Software 2.01 (GraphPad, San Diego, CA). Saturation analysis
yielded KD values of 20 and 17 pM for the
ETB receptor and the
ETB/EGFP fusion protein, respectively. The values
were used for calculations of the Ki values
of unlabeled ligands (displacement experiments).
Reappearance of ETB Receptors after Agonist-Mediated Internalization. CHO cells expressing the ETB receptor or the ETB/EGFP fusion protein were incubated with either buffer alone or with 100 nM ET1 in Ham's F12/10 mM HEPES, pH 7.4, for 30 min at 37°C. Unbound or nonspecifically bound ET1 was removed by two acid washes with DPBS (137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8.0 mM Na2HPO4, 1 mM CaCl2, 0.5 mM MgCl2)/50 mM acetic acid, pH 5.0, followed by another wash with Dulbecco's PBS (DPBS), pH 7.4. The cells were finally incubated in Ham's F12 medium supplemented with 10% heat-inactivated fetal calf serum in a humidified atmosphere of 95% air/5% CO2. After incubation at 37°C (0-240 min), cells were transferred onto ice and incubated with 100 pM 125I-ET1 in Ham's F12/10 mM HEPES, pH 7.4, for 1 h. In those experiments requiring inhibition of protein synthesis, cycloheximide (final concentration, 20 µg/ml) was present in all buffers throughout.
Time Course Studies of Ligand-Mediated Internalization. CHO cells were grown for 48 h on glass coverslips, washed once with PBS, and incubated with 100 nM Cy3-ET1 in Ham's F12 medium/10 mM HEPES, pH 7.4, for 30 min at 4° C. Bacitracin (final concentration, 213 µg/ml) was added to prevent unspecific absorption of the ligand to the surface of Petri dishes and reaction tubes. The samples were washed twice with ice-cold PBS and finally with prewarmed (37° C) Ham's F12 medium/10 mM HEPES, pH 7.4, and incubated for various periods (0-240 min) to allow internalization of the ligand/receptor complex. Cells were fixed with fixation buffer (2.5% paraformaldehyde in 100 mM sodium cacodylate; 100 mM sucrose, pH 7.5) for 30 min at RT, rinsed in PBS and mounted with Immu-Mount (Shandon, Pittsburg, PA) medium before imaging by confocal or epifluorescence microscopy.
Inhibition of Clathrin-Dependent Internalization.
Clathrin-dependent internalization is inhibited in hypertonic medium
(Daukas and Zigmond, 1985
; Heuser and Anderson, 1989
). CHO cells stably
expressing the ETB receptor were pretreated at 4° C for 30 min with Cy3-ET1 in Ham's F12 medium/10 mM HEPES, pH
7.4, without or with 0.2 to 0.45 M sucrose (final osmolarity of
500-750 mOsM). Unbound or nonspecifically bound ET1 was removed by two
acid washes with DPBS/50 mM acetic acid, pH 5.0, followed by two washes
with Ham's F12 medium/10 mM HEPES, pH 7.4, in the absence or presence
of 0.2 to 0.45 M sucrose and finally incubated for a further 60 min
until fixation. To verify that sucrose-treated cells remained viable,
control samples incubated for 60 min in Ham's F12 medium/10 mM HEPES,
pH 7.4, supplemented with 0.45 M sucrose were washed twice with Ham's
F12 medium/10 mM HEPES without sucrose, pH 7.4, and incubated in the
same medium for a further 60 min until fixation.
Colocalization of Fluo-ET1 with DiI-LDL or TRITC-Tfr.
TRITC-Tfr and DiI-LDL were, respectively used as marker proteins for
the recycling and lysosomally-directed pathways. CHO cells were either
serum-starved for 24 h to increase the expression of the
endogenous LDL receptors (Goldstein et al., 1983
) or treated for
24 h with 4 µM deferoxamine mesylate (chelates iron) to increase expression of transferrin receptors (Mattia et al., 1984
). Cells were
incubated with Fluo-ET1 and either TRITC-Tfr (20 µg/ml) or DiI-LDL
(10 µg/ml) at 18°C for 1 h to allow endocytosis of the respective ligands and to delay the exit from the early endosome (Dunn
et al., 1980
). After washing with cold medium cells were rapidly warmed
by placing the coverslip directly on a 37°C heat block for 2, 5, 10, 15, and 30 min to allow transport out of the early endosome. The cells
were then washed twice with ice-cold PBS and fixed as described above.
Fluorescence Microscopy and Image Analysis.
Fixed cells were
examined using a Leica DMLB epifluorescence microscope equipped with a
Plan-Fluotar 40 × 1.00 and Plan-Apo 100 × 1.40 oil
immersion objective (Leitz, Wetzlar, Germany) and fluorescein
isothiocyanate- and Cy3-selective filters. Images were recorded by
means of a 12-bit, cooled, charge-coupled device camera (Sensi Cam/CCD;
Sony, Tokyo, Japan). Video images were processed with Axiovision 2.0 software (Zeiss, Oberkochen, Germany). In addition, after DiI-LDL or
TRITC-Tfr labeling, the fixed samples were analyzed on a Zeiss 410 invert laser scanning microscope (Argon/Krypton and Argon-Ion laser).
Excitation and emission wavelengths were
exc = 364 nm and
em > 420 nm for Hoe33258,
exc = 488 nm and
em > 515 nm for Fluo-ET1 and EGFP, and
exc = 543 nm and
em > 570 nm for Cy3-ET1, TRITC-Tfr,
and DiI-LDL.
| |
Results |
|---|
|
|
|---|
For visualization of the ETB receptor and
the endogenous ligand ET1, we generated fusion proteins consisting of
the full-length ETB receptor and the EGFP (fused
to the C terminus) and ET1 conjugated with Fluo or Cy3 (Fig.
1). CHO cells stably expressing either the native ETB receptor or the
ETB/EGFP fusion protein were generated (two
independently isolated clones were used in each case) and analyzed in
displacement experiments to ascertain whether the presence of EGFP at
the C terminus of the ETB receptor alters its
binding properties. To this end, membrane preparations were analyzed
using 125I-ET1 as radiolabeled ligand.
Displacement of 125I-ET1 was studied using the
endogenous ligands ET1 and ET3, the synthetic ETB
receptor selective antagonist BQ788, the ETA
receptor selective antagonist BQ123, or the nonselective antagonist
PD145065. Ki values were very similar for
the ETB receptor and the
ETB/EGFP fusion protein in all cases (Table
1). In addition, we analyzed the
Ki values of Cy3-ET1 and Fluo-ET1 with
membranes derived from CHO cells expressing the
ETB receptor or the
ETB/EGFP fusion protein. Compared with ET1
itself, Fluo-ET1 displayed very similar and Cy3-ET1 5-fold lower
affinities to the ETB receptor and
ETB/EGFP fusion protein (Table 1).
|
|
The presence of intact (nondegraded) ETB
receptors and ETB/EGFP fusion proteins was
demonstrated by LT-PAGE analysis. Membranes of CHO cells expressing
either the native ETB receptor or the ETB/EGFP fusion protein were incubated with 200 pM 125I-ET1 for 2 h at 25°C. Because ET1
remains tightly bound to the receptor without cross-linking, the
ligand/receptor complex can be identified by LT-PAGE and
autoradiography (Takasuka et al., 1994
). Two prominent major bands were
detected in both preparations. For the ETB
receptor bands migrating at about 34 and 45 kDa (Fig. 2, lane 2, from left to right) and for
ETB/EGFP fusion proteins bands at about 59 and 70 kDa (Fig. 2, lane 4) were observed. The specificity of the bands was
demonstrated in a control incubation in which
125I-ET1 competed with an excess of unlabeled ET1
(Fig. 2, lanes 1, 3). The more slowly migrating bands at 45 kDa (Fig.
2, lane 2) and 70 kDa (Fig. 2, lane 4) seem to represent the
full-length receptor without or with the EGFP moiety, respectively. The
bands migrating at 34 kDa (Fig. 2, lane 2) and 59 kDa (Fig. 2, lane 4)
most likely represent ETB receptors after
proteolytic cleavage within the extracellular N terminus as reported
previously (Hagiwara et al., 1991
; Akiyama et al., 1992
). This seems to
be caused by metal proteinases released during the preparation of
membrane fractions (Hagiwara et al., 1991
). Thus the
ETB receptor and the ETB/EGFP fusion protein behave identically. The
two bands found for the ETB/EGFP fusion protein
were clearly different from those detected for the
ETB receptor, indicating that significant
cleavage at the fusion site (leading to the formation of unfused
ETB receptor) does not occur.
|
On the basis of these results, we analyzed receptor internalization and
trafficking in CHO cells. Intact CHO cells were treated for 30 min at
4°C with 100 nM Cy3-ET1 so as to occupy ETB
receptors quantitatively. After an acid wash to remove unbound and
nonspecifically bound Cy3-ET1, the cells were either fixed immediately
(0 min) or incubated at 37°C (up to 4 h) before fixation.
Results of the time-lapse studies are depicted in Fig.
3 and show images of EGFP fluorescence
(Fig. 3, left column, green color), of the Cy3 fluorescence (Fig. 3,
middle column, red color) or an overlay of both signals (Fig. 3, right
column, resulting in the yellow color where green and red signals
colocalize). Immediately after the end of the labeling period (0 min),
EGFP and Cy3 signals were found to colocalize at the cell surface (Fig.
3, first row). In addition, EGFP but not Cy3 signals were also detected
in the interior of the cells (Fig. 3, arrows in the top row). Because
these signals were found in the perinuclear region, as was evident from
counterstaining of the nucleus (not shown), we assume that they
represent newly synthesized ETB/EGFP fusion
proteins located in the Golgi apparatus. These perinuclear signals for
EGFP were observed throughout the complete internalization protocol
(Fig. 3, arrows in the top row, see also entire left and right column).
They were abolished in cells pretreated with cycloheximide (Fig. 5,
upper right). After 5 min, internalization was observed as
indicated by a marked decrease of fluorescent signals at the cell
surface and the appearance of multiple vesicular patterns within the
cell (Fig. 3, arrowheads in the second row). Again, the overlay
indicated a colocalization of receptor and ligand. After 15 min of
incubation, the EGFP and Cy3 signals were found within larger
structures close to the nucleus; these compartments may represent late
endosomes. Cy3 or EGFP signals were barely detectable at the plasma
membrane at this stage. Similar results were obtained after 30-min
incubation, with the exception that the Cy3 and EGFP fluorescence
appeared around the nucleus (Fig. 3, double arrows) and began to
cluster on one side of the nucleus. The EGFP and Cy3 images were still
very similar. No reappearance of fluorescent signals at the cell
surface was observed, suggesting that recycling of the receptor did not
occur. After 60 min, fluorescent EGFP and Cy3 signals tended to a more
peripheral distribution within the cells; they did not dissociate.
After 2 and 4 h incubation, this peripheral distribution became
more pronounced, especially in cells with a polygonal shape; in cells
with an extended morphology, the signals were observed at the extreme
ends (Fig. 5 upper left). The EGFP signals decreased over time, most
likely because of proteolysis of the ETB/EGFP
fusion protein. However, reduced fluorescence of EGFP in the acidic
compartments of the late endosomes or lysosomes has also to be
considered (Patterson et al., 1997
; Llopis et al., 1998
) (Fig. 3,
bottom row; Fig. 5 upper row. Note the stronger red fluorescence
in both images). In contrast, Cy3 fluorescence (in the Cy3-bombensin
ligand) was reported to be stable in the range of pH 2.5 to 7.5 (Slice
et al., 1998
). No differences in the distribution of Cy3-ET1 signals
were found in cells expressing the ETB receptor
with or without the EGFP moiety (not shown).
|
In addition to using fluorescence microscopy, we demonstrated the
sustained ligand-mediated internalization of the
ETB receptor by the more sensitive binding assay
using 125I-ET1. Standard protocols for
determining receptor internalization involving acidic stripping to
remove bound ligand present at the cell surface are not applicable to
the ETB receptor. The ligand ET1 remains tightly
bound with a dissociation half-life of more than 30 h (Waggoner et
al., 1992
). We were even unable to efficiently remove bound ET1 at pH
3.0 or after limited tryptic digestion (not shown). Therefore, we
analyzed the reappearance of 125I-ET1 binding
sites after prior incubation of cells with 100 nM ET1 for 30 min. After
incubation with ET1, cells were washed twice with DPBS/50 mM AcOH, pH
5.0, to remove nonspecifically bound ET1 and further incubated in
complete medium for different times (0-240 min). Immediately after the
preincubation period, barely any specific binding was detectable,
consistent with the fact that ET1 is tightly bound to the
ETB receptor and that the acidic wash is
insufficient to remove it (Fig. 4).
Within 30 min, the number of binding sites at the cell surface
increased continuously and almost reached control values after 4 h. This time course of reappearance of ET1-binding sites was very
similar for CHO cells expressing either the native
ETB receptor or the
ETB/EGFP fusion protein (compare Fig. 4, A, C,
with Fig. 4, B, D), again indicating that the EGFP moiety did not
affect receptor trafficking. The reappearance of
ETB receptors could be caused either by recycling (which, in the light of the microscopical analysis, is unlikely) or by
synthesis of new receptor. Therefore, we performed the binding experiment in the presence of cycloheximide (which was added together with ET1) to block the synthesis of new receptors. Under these conditions, no binding sites were detected at up to 4 h after stimulation of CHO cells expressing the ETB
receptor or the ETB/EGFP fusion protein. These
results were confirmed by microscopical studies. When cells were
incubated for an additional 2 h after stimulation with ET1,
colocalization of the ETB/EGFP fusion protein and
Cy3-ET1 was observed, as indicated by yellow areas in the overlay
presentation (Fig. 5, upper left). In
addition, signals for the EGFP (Fig. 5, upper left, green color) but
not Cy3 were found around the nucleus (arrowheads, probably
representing newly synthesized receptors) or at the plasma membrane
(arrows); these signals were not evident in the presence of
cycloheximide (Fig. 5, upper right). Similar results were obtained with
CHO cells expressing the native ETB receptor
(Fig. 5, bottom row). For the experiments with the native
ETB receptor, cells were exposed to Fluo-ET1 for
30 min and incubated for 4 h. After this period, cells were
incubated with Cy3-ET1. The strong labeling of the cell surface
demonstrated the presence of binding sites at the plasma membrane (Fig.
5, lower left). In the presence of cycloheximide, hardly any binding of
Cy3-ET1 to the cell surface was detected (Fig. 5, lower right), further
supporting the conclusion that the binding sites at the cell surface
had arisen from new synthesis.
|
|
To elucidate the mechanisms responsible for internalization of the
ETB receptor, we analyzed the receptor-mediated
uptake of Cy3-ET1 in the absence and presence of 0.45 M sucrose.
Hypertonic medium is known to block the clathrin-mediated pathway of
internalization (Daukas and Zigmond, 1985
; Heuser and Anderson, 1989
).
In the absence of sucrose, Cy3-ET1 was internalized rapidly and found in the periphery and around the nucleus of the cell within 1 h (Fig. 6A). In contrast, Cy3-ET1 was not
internalized in the presence of sucrose but remained at the cell
surface (Fig. 6B). After replacing the hypertonic by normotonic medium,
internalization of Cy3-ET1 was detectable, proving that cells remained
viable despite the hyperosmolar treatment (Fig. 6C). A marked
inhibition of internalization was also observed in the presence of 0.2 M sucrose, although it was less effective than that observed in the
presence 0.45 M sucrose (not shown). The results are in agreement with
previous reports (Daukas and Zigmond, 1985
; Heuser and Anderson, 1989
).
|
Using TRITC-Tfr and DiI-LDL, we analyzed the route of
intracellular trafficking of the ETB receptor.
TRITC-Tfr is a marker for the recycling pathway, and DiI-LDL is a
marker for the lysosomally-directed pathway (Ghosh and Maxfield, 1995
).
After binding of TRITC-Tfr to the transferrin receptor the complex is
internalized via clathrin-mediated endocytosis. The complex is
transported to early endosomes, in which the acidic environment favors
the dissociation of Fe2+ from transferrin. The
transferrin receptor/apotransferrin complex cycles back to the cell
surface, where the apotransferrin is released. DiI-LDL binds to the LDL
receptor and the complex is also internalized via the clathrin-mediated
pathway (Chen et al., 1990
). LDL subsequently dissociates from the
receptor and is sorted to the lysosomal pathway, and the LDL receptor
recycles to the plasma membrane (Mayor et al., 1993
; Ghosh and
Maxfield, 1995
). CHO cells expressing the ETB
receptor were incubated with Fluo-ET1 and either TRITC-Tfr or DiI-LDL
for 1 h at 18°C to allow internalization but to delay exit from
early endosomes. Under these conditions, Fluo-ET1 and TRITC-Tfr show a
very similar distribution (Fig. 7, upper
row). Incubation at 37°C for 5 min led to a separation of Fluo-ET1
and TRITC-Tfr signals (Fig. 7, middle row). Fluo-ET1 was mainly
observed in distinct vesicular structures (arrowheads); TRITC-Tfr
displayed more diffuse, multiple vesicular patterns (arrows) separating from the distinct larger vesicular structures (arrowheads). At later
time points (10 to 15 min), the TRITC-Tfr signal was no longer
detectable (not shown), indicating a complete recycling of
apotransferrin. In contrast, DiI-LDL and Fluo-ET1 exhibited an almost
identical distribution within relatively large vesicular structures
after this 5 min incubation period at 37°C and at later time points
(up to 30 min, not shown; Fig. 7, bottom row). The data support the
conclusion that Fluo-ET1 and DiI-LDL follow the same trafficking route,
whereas the route of TRITC-Tfr differs from that of
Fluo-ET1.
|
| |
Discussion |
|---|
|
|
|---|
The use of fusion proteins comprising the
ETB receptor and EGFP in conjunction with
fluorescent ET1 allowed visualization of the internalization and
intracellular trafficking of both receptor and ligand. The presence of
the EGFP moiety did not seem to alter the functional properties of the
receptor, in that no significant difference between the native
ETB receptor and the fusion protein was observed
in 125I-ET1 displacement experiments with
membrane preparations using various ET receptor ligands (Table 1). We
also measured the ET1-mediated activation of phospholipase C
(determined by inositol phosphate formation) and found no differences
between the ETB receptor and the
ETB/EGFP fusion protein (data not shown).
Regarding internalization initiated by Cy3-ET1, essentially similar
results were obtained with CHO cells expressing either the native
ETB receptor or the ETB/EGFP fusion protein (Figs. 3 and 5). In
addition, the reappearance of 125I-ET1 binding
sites at the cell surface after pretreatment with ET1 was comparable
for both the native ETB receptor and the
ETB/EGFP fusion protein (Fig. 4). The results
also indicate that the intracellular trafficking of the receptor was
not altered by the EGFP moiety. Our data are in agreement with those
reported for other GPCRs bearing green fluorescent protein or its
variants at the C terminus (Barak et al., 1997
; Tarasova et al., 1997
;
for review and further references, see Milligan 1999
).
For the cholecystokinin receptor, the angiotensin II type 1a receptor,
the gastrin-releasing peptide receptor, and the gonadotropin-releasing hormone receptor, internalization with fluorescent ligands has been
studied (Roettger et al., 1995
; Hein et al., 1997
; Slice et al., 1998
;
Cornea et al., 1999
). After internalization and sorting of the
receptor/ligand complex into endosomal compartments, separation of the
fluorescent ligands from the receptors was observed; the fluorescent
ligands remained in endosomal and/or perinuclear vesicles, whereas the
receptors recycled to the cell surface. This is in contrast to our
findings demonstrating that both ETB receptor and
the fluorescent ligand remain colocalized for up to 4 h. Because
the structures harbouring the receptor/ligand complexes were also
stained with DiI-LDL, we assume that they represent late endosomes or
lysosomes (Fig. 7).
The molecular mechanisms directing the ligand bound
ETB receptor to the late endosomal/lysosomal
pathway remain speculative. In general, it is assumed that transport to
lysosomes via multivesicular bodies represents a specific,
signal-mediated process, whereas recycling of membrane receptors such
as the transferrin receptor follows bulk flow (for review, see
Gruenberg and Maxfield, 1995
). In the GPCR family, lysosomally-directed
sorting has so far only been reported for the LH/hCG receptor (Ghinea
et al., 1992
) and the subfamily of PARs (Hein et al., 1994
; Trejo and
Coughlin, 1999
; Déry et al., 1999
). In the latter, thrombin
(PAR1, PAR3) and trypsin (PAR2) cleave a portion of the receptor's
amino terminus, thereby generating a new amino terminus that functions
as a tethered ligand. Sorting to lysosomes and degradation represents
the only efficient mechanism to prevent continuous activation
(Déry et al., 1999
; Trejo and Coughlin, 1999
).
In the case of the ETB receptor, the
quasi-irreversible binding of ET1 (Waggoner et al., 1992
) may provide
the basis for the sorting to the endosomal/lysosomal pathway. The
ligand remains bound even to the partially denatured receptor, as shown
by LT-PAGE analysis (Fig. 2; Takasuka et al., 1994
). Acidic treatment
also failed to remove bound ET1 from the ETB
receptor. DPBS at pH 5.0 was found suitable to remove unbound or
unspecifically bound Cy3-ET1 (Figs. 3 and 5) but failed to remove
specifically bound ligand. Likewise, acidic stripping at pH 3.0 was not
effective. The resistance of the ligand/receptor complex to low pH
values may be of physiological significance. Our data suggest that the
ligand cannot be removed from the receptor in acidic compartments such
as early or late endosomes (whose pH values are reported to range from
6.0 to 6.2 and from 5.0 to 5.5, respectively; reviewed in Gruenberg and
Maxfield, 1995
). In addition, the prolonged presence of ligand and
receptor in the same structure argues against a significant proteolysis of the ligand within early and late endosomes, which could
(alternatively to the acidic environment) enable recycling of the free
ETB receptor.
The continuous presence of the ligand at the receptor may,
however, be a prerequisite for lysosomal targeting rather than being
itself sufficient to direct sorting to late endosomes/lysosomes. In the
case of PAR1, it was demonstrated that the C terminus contains signals
required for its transport to the lysosome. The neurokinin 1 (NK1) receptor, which recycles, is redirected to
lysosomes after replacement of its intracellular C terminus by that of
PAR1. A chimera of PAR1 with the C terminus of the
NK1 receptor is, conversely, no longer targeted
to the lysosomes but cycles back to the cell surface (Trejo and
Coughlin, 1999
). Neither the amino acid residues in the
NK1 receptor C terminus, which mediate recycling,
nor those in the PAR1 receptor, which direct lysosomal targeting, have
been identified.
We show here that ligand-occupied ETB
receptors are internalized via the clathrin-mediated pathway, resulting
in a transient down-regulation, and that reappearance of
ETB receptors at the cell surface requires
protein synthesis. In direct contrast, the ETA
receptor has been shown to internalize via caveolae (Chun et al., 1994
)
and to show substantial recycling upon ET1 treatment of cultured aortic
myocytes and of aortic rings (Marsault et al., 1993
). These fundamental
differences in the behavior of ETA and ETB receptors fit the observation that repeated
bolus application of ET1 causes a tachyphylaxis of the vasodilatory
response (mediated via endothelial ETB
receptors), whereas vasoconstriction (mainly mediated via vascular
smooth muscle ETA receptors) is preserved (Le
Monnier de Gouville et al., 1990
). The different modes of internalization could provide a basis for the enhanced vasoconstrictory response in disease states associated with transiently (pre-eclampsia, acute ischemic stroke, subarachnoidal hemorrhage, myocardial
infarction) or chronically (endstage renal failure, pulmonary
hypertension) increased ET1 plasma levels (for review, see Sokolovsky,
1995
). Further studies with isolated blood vessels from animal models or from patients are required to elucidate differences in the expression of ET receptor subtypes of smooth muscle and endothelial cells.
| |
Acknowledgments |
|---|
We thank Dr. Gisela Papsdorf for help in generating CHO clones expressing the ETB receptor and the ETB/EGFP fusion protein. We greatly appreciate the technical support of Jenny Eichhorst and Heidi Hans. We thank John Dickson for critically reading the manuscript and Dr. Ralf Schülein for helpful discussions.
| |
Note Added in Proof. |
|---|
After submission of the
manuscript, Abe et al. (J Biol Chem 275:8664-8671,
2000) reported on the internalization of ETB receptors
transiently expressed in Ltk
cells.
| |
Footnotes |
|---|
Received December 29, 1999; Accepted February 25, 2000
The work was supported by the Deutsche Forschungsgemeinschaft (FG 341) and the Fonds der Chemischen Industrie.
Send reprint requests to: Dr. Alexander Oksche, Forschungsinstitut für Molekulare Pharmakologie, Alfred-Kowalke-Str. 4, D-10315 Berlin. E-mail: oksche{at}fmp-berlin.de
| |
Abbreviations |
|---|
ET1, endothelin 1; ET2, endothelin 2; ET3, endothelin 3; ETA, human endothelin A; ETB, human endothelin B; GPCR, G protein-coupled receptor; GRK, G protein-coupled receptor kinase; CHO, Chinese hamster ovary; EGFP, enhanced green fluorescent protein; LDL, low-density lipoproteins; LH/hCG receptor, luteinizing hormone/human choriogonadotropin receptor; PAR, protease-activated receptor; TRITC, tetramethylrhodamine isothiocyanate; Tfr, transferrin; DiI, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine; Cy3, Cyanin3; Fluo, 5(6)-carboxyfluorescein-N-hydroxysuccinimide ester; LT-PAGE, low temperature-polyacrylamide gel electrophoresis; BAME, bacitracin/aprotinin/MgCl2/EGTA; DPBS, Dulbecco's PBS; NK1, neurokinin 1.
| |
References |
|---|
|
|
|---|
2-adrenergic receptor-green fluorescent protein conjugate.
Mol Pharmacol
51:
177-184
beta-arrestin-dependent endocytosis of a proteinase receptor.
J Biol Chem
274:
18524-18535This article has been cited by other articles:
![]() |
N. J. Evans and J. W. Walker Endothelin Receptor Dimers Evaluated by FRET, Ligand Binding, and Calcium Mobilization Biophys. J., July 1, 2008; 95(1): 483 - 492. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-T. Bawolak, L. Gera, G. Morissette, J. M. Stewart, and F. Marceau B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-bradykinin) Is an Inactivation-Resistant Agonist of the Bradykinin B2 Receptor Derived from the Peptide Antagonist B-9430 (D-Arg-[Hyp3,Igl5,D-Igl7,Oic8]-bradykinin): Pharmacologic Profile and Effective Induction of Receptor Degradation J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 534 - 546. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hatae, N. Aksentijevich, H. W. Zemkova, K. Kretschmannova, M. Tomic, and S. S. Stojilkovic Cloning and Functional Identification of Novel Endothelin Receptor Type A Isoforms in Pituitary Mol. Endocrinol., May 1, 2007; 21(5): 1192 - 1204. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Dai and J. J. Galligan Differential Trafficking and Desensitization of Human ETA and ETB Receptors Expressed in HEK 293 Cells. Experimental Biology and Medicine, June 1, 2006; 231(6): 746 - 751. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Grantcharova, H. P. Reusch, M. Beyermann, W. Rosenthal, and A. Oksche Endothelin A and Endothelin B Receptors Differ in Their Ability to Stimulate ERK1/2 Activation. Experimental Biology and Medicine, June 1, 2006; 231(6): 757 - 760. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Grantcharova, H. P. Reusch, S. Grossmann, J. Eichhorst, H.-W. Krell, M. Beyermann, W. Rosenthal, and A. Oksche N-Terminal Proteolysis of the Endothelin B Recept |